<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381261</url>
  </required_header>
  <id_info>
    <org_study_id>2017P001813</org_study_id>
    <nct_id>NCT03381261</nct_id>
  </id_info>
  <brief_title>(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist</brief_title>
  <official_title>Novel Concepts for OnabotulinumtoxinA (Botox) Mechanisms of Action: Role in Altering the Molecular Environment in Which Pain Fibers Exist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare Botox-treated and Botox-untreated symptomatic tissues (defined as areas where the
      head hurts and the pain is felt) of chronic migraine (CM) patients using molecular studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients for migraine surgery will be injected unilaterally with Botox prior to
      surgery. The effects of Botox on tissues will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>molecular markers in discarded tissue of migraine patients</measure>
    <time_frame>one year</time_frame>
    <description>molecular markers in discarded tissue of migraine surgery will be analyzed. Gene Expression CodeSet profiling 594 genes; 579 immunology-related human genes + 15 internal reference controls.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin type A injection arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be injected with Botulinum toxin on one side of the back of the head.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <description>Injection of Botulinum toxin type A in back of head</description>
    <arm_group_label>Botulinum toxin type A injection arm</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years

          -  Diagnosis of Chronic Migraine consistent with International Classification of Headache
             Disorders (ICHD-III) criteria, with a history of bilateral headache pain and chronic
             tenderness in neck muscles

          -  Patient is capable and willing to provide informed consent

          -  Female subjects of child bearing potential must have a negative pregnancy test at
             enrollment and agree to remain abstinent or use acceptable methods of birth control
             (i.e., hormonal contraceptives, inrauterine device, diaphragm with spermicide,
             cervical cap or sponge, condoms or partner has had a vasectomy) for three months
             following injections of Botox

          -  Patients referred by their primary Neurologist to the study surgeon and who are
             determined to be candidates for surgical decompression of extracranial sensory nerves.

          -  Patient agrees to abstain from protocol-specific excluded medications beginning 14
             days prior to the decompression surgery.

        Exclusion Criteria:

          -  Patient has hypersensitivity reactions or other intolerance to Botox

          -  Patient is pregnant or trying to become pregnant with the timeframe of the study.

          -  Infection at proposed injection sites.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William G. Austen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William G Austen</last_name>
    <phone>6174599106</phone>
    <email>wausten@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Gfrerer</last_name>
    <phone>6174599106</phone>
    <email>lgfrerer@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William G. Austen, MD</last_name>
      <phone>617-459-9106</phone>
      <email>wausten@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Gfrerer, MD PhD</last_name>
      <phone>6174599106</phone>
      <email>lgfrerer@partners.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>William Gerald Austen</investigator_full_name>
    <investigator_title>Chief, Plastic and Reconstructive Surgery; Chief, Burn Surgery</investigator_title>
  </responsible_party>
  <keyword>chronic migraine</keyword>
  <keyword>trigeminal neuralgia</keyword>
  <keyword>migraine surgery</keyword>
  <keyword>nerve decompression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

